Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,629 INR | +1.33% | +2.50% | +23.02% |
Jun. 05 | Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada | MT |
May. 30 | India's pharma export sales to grow faster this year, trade body says | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With an expected P/E ratio at 37.17 and 30.44 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.81 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.02% | 8.78B | A | ||
+43.64% | 754B | C+ | ||
+39.49% | 630B | B | ||
-6.58% | 352B | C+ | ||
+19.72% | 331B | B- | ||
+8.78% | 298B | C+ | ||
+11.70% | 217B | B- | ||
-1.76% | 216B | A+ | ||
+0.03% | 163B | C+ | ||
+6.13% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LUPIN Stock
- Ratings Lupin Limited